1378549-07-5
1378549-07-5
Chemical Structure
Bazlitoran
Synonym(s): IMO-8400
- CAS 番号: 1378549-07-5
- Formula:C179H233N52O101P17S17
- Molecular Weight:5800.70
SMILES: [Bazlitoran]
Biological Activity: Bazlitoran (IMO-8400) is an oligonucleotide-based TLR7/8/9 antagonist. Bazlitoran blocks the activation of Toll-like receptors 7, 8, and 9. Bazlitoran inhibits cytokine responses mediated by Toll-like receptors 7, 8, and 9. Bazlitoran is associated with injection site reactions. Bazlitoran improves moderate-to-severe plaque psoriasis[1][2].
| 製品番号 | 製品名 | 純度 | 製品説明 | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
Bazlitoran | 95.30% | Bazlitoran (IMO-8400) is an oligonucleotide-based TLR7/8/9 antagonist. Bazlitoran blocks the activation of Toll-like receptors 7, 8, and 9. Bazlitoran inhibits cytokine responses mediated by Toll-like receptors 7, 8, and 9. Bazlitoran is associated with injection site reactions. Bazlitoran improves moderate-to-severe plaque psoriasis. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
References
- [1]. Kim YJ, et al. A phase 2, double-blinded, placebo-controlled trial of toll-like receptor 7/8/9 antagonist, IMO-8400, in dermatomyositis. J Am Acad Dermatol. 2021 Apr;84(4):1160-1162. [Content Brief]
- [2]. Balak DM, et al. IMO-8400, a toll-like receptor 7, 8, and 9 antagonist, demonstrates clinical activity in a phase 2a, randomized, placebo-controlled trial in patients with moderate-to-severe plaque psoriasis. Clin Immunol. 2017;174:63-72. [Content Brief]
